Gilead Sciences

Gilead Sciences

Yahoo Finance • 2 hours ago

Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story

NEW YORK, Nov. 4, 2026 /PRNewswire/ -- Fly on Wall Street News Commentary - Wall Street's major indexes rallied together on Wednesday. As of 2:31 p.m. ET, the Dow Jones Industrial Average was up 1,552.12 points, or 3.0%, at 53,338.84, whil... Full story

Yahoo Finance • 2 days ago

Gilead (GILD) Stock Fair Value Edges Higher After Analyst Target Increases

Price targets for Gilead Sciences have shifted higher, with the updated fair value estimate moving from US$158.65 to US$165.31. Recent Street research describes a tilt toward higher targets, as analysts weigh Q3 execution, the HIV franchis... Full story

Yahoo Finance • 3 days ago

What Avantis U.S. Equity ETF (AVUS) Bought: Exxon Mobil Leads on Oct. 29

This article first appeared on GuruFocus. Avantis U.S. Equity ETF (AVUS) added to its portfolio last Thursday, with net buying of $213.4 million against $226.2 million in gross ETF activity. The fund increased 434 positions and trimmed 53... Full story

Yahoo Finance • 5 days ago

Gilead's HIV Franchise Supports Growth Outlook, RBC Says

Gilead Sciences (GILD) continues to benefit from strong demand for its HIV medicines, helping suppor Keep reading this article with Yahoo Finance Plus Silver Upgrade to Silver Silver Premium news Full access to Financial Times and MT N... Full story

Yahoo Finance • 6 days ago

Gilead outlines ~$1.5B 2028 biktarvy revenue impact as 2026 base business guidance rises to $30.7B-$31.0B

Earnings Call Insights: Gilead Sciences (GILD) Q3 2026 MANAGEMENT VIEW * "Gilead delivered an exceptional third quarter that highlights the strength, breadth and durability of the business." (Chairman & CEO Daniel O'Day) "Third quarter... Full story

Yahoo Finance • 6 days ago

Alphabet drops 12% in deepening tech and semiconductor rout

A steep 12.6% sell-off in Alphabet (GOOGL) dragged down the broader market, pulling semiconductor and software names like Micron (MU), Intel (INTC), and Marvell (MRVL) deep into negative territory. Bucking the tech retreat, healthcare stoc... Full story

Yahoo Finance • 6 days ago

Gilead’s HIV Franchise Powers Earnings Beat. The Rest Is a Work in Progress.

Gilead Sciences posts higher-than-expected sales as blockbuster HIV drug Biktarvy continues to drive its top line. Continue Reading... Full story

Yahoo Finance • 7 days ago

Stock market today: Dow rises, S&P 500 and Nasdaq futures fall as Alphabet stock sells off, AI jitters return

US stock futures diverged in premarket trading on Thursday as Alphabet's Q3 earnings sparked a sell-off in the stock and AI jitters returned to markets, dragging on the tech-heavy indexes. Futures on the Dow Jones Industrial Average (YM=F... Full story

Yahoo Finance • 10 days ago

Google, Microsoft, Amazon, and the Fed step up to a skittish market: What to watch this week

The first week of Big Tech earnings looked promising — until Thursday hit. After SpaceX (SPCX), Meta (META), and Tesla (TSLA) opened their books without signaling ballooning spending next year, the reality that longer-term projects would,... Full story

Yahoo Finance • 10 days ago

Earnings Week Ahead: MSFT, GOOGL, AMZN, XOM, BA, VZ, and more

[Rolled newspaper with the headline Quarterly Results] Zerbor Another heavyweight earnings week is ahead, with results from Big Tech, energy giants, chipmakers, financial services, healthcare, and industrial leaders set to offer a broad r... Full story

Yahoo Finance • 13 days ago

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks rose late Thursday afternoon with the NYSE Healthcare Index adding 1.7% and the St PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 14 days ago

BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer

BioNTech SE BioNTech enters a clinical trial collaboration with Gilead Sciences with the aim of improving outcomes in patients with PD-L1 low or negative triple-negative breast cancer The global Phase 3 ROSETTA Breast-01 trial will evolve... Full story

Yahoo Finance • 16 days ago

1 Unprofitable Stock with Exciting Potential and 2 We Find Risky

1 Unprofitable Stock with Exciting Potential and 2 We Find Risky Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending int... Full story

Yahoo Finance • 19 days ago

Coca-Cola, Visa and Mastercard Hit Records as Investors Rotate Out of Chip Stocks

Coca-Cola, Visa and Mastercard are among the stocks hitting records as investors look beyond the AI trade. Earnings could help broaden the rally. Continue Reading... Full story

Yahoo Finance • 20 days ago

3 Inflated Stocks Walking a Fine Line

3 Inflated Stocks Walking a Fine Line Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions. However,... Full story

Yahoo Finance • 21 days ago

Vir Biotechnology, Gilead Sciences to Develop Dual-Masked T-Cell Engagers for Solid Tumors

Vir Biotechnology (VIR) has signed a collaboration and license agreement with Gilead Sciences (GILD) PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 21 days ago

Vir jumps on Gilead licensing deal worth up to $1.9B for cancer drugs

[Two coloured ropes knotted together] Vir Biotechnology (VIR [https://seekingalpha.com/symbol/VIR]) traded nearly 10% higher in the premarket on Wednesday after announcing a licensing agreement worth up to nearly $1.9B with Gilead (GILD [... Full story

Yahoo Finance • 23 days ago

Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?

Biogen Inc. (NASDAQ:BIIB) closed at $225.71 on October 9. The stock has returned 30.5% during the last six months, compared to a 24.3% return for the Insider Monkey Billionaire Index and 15.1% for the State Street SPDR S&P 500 ETF Trust.... Full story

Yahoo Finance • 23 days ago

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Nurix Therapeutics, Inc. Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobrutideg combination strategy with initiation of recruiti... Full story

Yahoo Finance • 23 days ago

Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says

Gilead Sciences' (GILD) HIV prevention drug Yeztugo's long-term growth outlook is supported by a phy PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story